Juvederm: Products, Cost, Results and Where to Get It

Juvederm is Allergan's collection of hyaluronic acid (HA) dermal fillers.

Allergan describes the collection as six FDA-approved HA fillers — Voluma XC, Volux XC, Vollure XC, Volbella XC, Ultra Plus XC and Ultra XC — covering cheeks, chin, temples, smile lines, lips, under-eyes and jawline, and says the line treats 10 areas of the face in all.

Allergan also says all six fillers contain pain-reducing lidocaine.

Hyaluronic acid is a sugar (polysaccharide) that the FDA describes as naturally present in skin and cartilage; the HA in fillers is made from bacteria or rooster combs and is often chemically crosslinked so that it holds up longer.

Legally, these are regulated as medical device implants rather than as drugs: FDA approves dermal fillers through premarket approval (PMA) and describes them as implants approved to create a smoother and/or fuller appearance in the face — including the nasolabial folds (smile lines), cheeks, chin, lips and back of the hands.

The dated Juvederm approvals in this guide — Voluma XC, Volux XC, Vollure XC, Volbella XC, Ultra XC for the lips, and SKINVIVE — are each for adults over 21.

FDA's general statement is that fillers are approved for adults aged 22 or older — meaning over 21 — with each product's label setting the exact age.

All six Juvederm products are hyaluronic acid.

FDA groups HA with calcium hydroxylapatite and poly-L-lactic acid (the material in Sculptra) as the absorbable, temporary filler materials; the dermal fillers guide covers the other brands and materials.

SKINVIVE by Juvederm is related but counted separately: FDA approved it in 2023 to improve cheek skin smoothness and expanded it to neck lines in 2026, while Allergan counts six fillers in the Juvederm collection and does not list SKINVIVE among them.

Each Juvederm product carries its own approved indications, and one product's approval never transfers to another.

Every approval below is a premarket approval (PMA) — the path FDA uses for fillers, which it regulates as medical device implants — with the dates taken from FDA's PMA records.

Notice how narrow each approval is.

Ultra XC is approved for the lips; Ultra Plus XC is not. Voluma XC's approvals cover cheeks, chin and temples — not lips.

Any use outside the product's own label, such as Volbella XC in the jawline or any Juvederm filler in the nose, is off-label: it is not on any current US label for that product.

The off-label territory does not end at the examples above: FDA's PMA approval orders on file as of October 2026 show no US filler with an approved indication for the nose, the glabella, the forehead, the buttocks/hips or the breasts.

For lips specifically, the two approved Juvederm options are Ultra XC (2015) and Volbella XC (2016); the lip filler guide covers the approved lip fillers, cost and results.

There is no single Juvederm price.

Allergan's consumer site says Juvederm treatment can range from "$600–$1,400", with the total varying by the products chosen and by provider — a manufacturer figure, read on Allergan's site in October 2026, that Allergan does not break down per syringe or per treatment.

ASPS, the plastic surgery professional society, lists average costs of $715 for hyaluronic acid fillers and $743 for lip augmentation with filler.

Those are average fees reported by ASPS member plastic surgeons — not med spa prices — and the ASPS page does not state the data year.

What moves the price: ASPS names the injector's expertise and qualifications, the type of procedure, the time and effort involved, and the geographic location of the office.

ASPS also notes that health insurance does not cover dermal fillers.

Maker programs can discount the sticker price: Allergan's Allē loyalty program gives 100 points = $10 toward qualifying treatments, including Juvederm.

None of the national figures above sets the price at any particular practice.

Ask any provider you are considering for a written quote that names the exact product and the amount before you book.

It depends on the product and the area, because each carries its own data.

FDA's material-level estimate is that the effects of hyaluronic acid fillers "last approximately 6 – 12 months", and FDA groups HA among the absorbable (temporary) filler materials — no Juvederm product is a permanent filler.

Allergan states its own maximums for each product and area "with optimal treatment," and several of them run past FDA's material-level estimate.

Allergan's stated maximums:

Read those for what they are: manufacturer "up to" claims on the maker's own website — stated maxima rather than averages, and not a promise of any individual result.

Allergan says Juvederm results are visible immediately after treatment, and that the products are injected with a needle or a cannula.

Its safety information also lists swelling among the most common side effects, most of which resolve within 30 days — so the first days are not the finished picture.

Juvederm's own Important Safety Information (ISI) names the most common side effects: redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration and itching — plus dryness with Volbella XC — and says most resolve within 30 days.

The ISI adds that persistent side effects may be treated with antibiotics, steroids or hyaluronidase.

FDA's filler-wide list is broader.

Common risks: bruising, redness, swelling, pain, tenderness, itching and rash.

Less common: nodules or granulomas, infection, allergic reaction and necrosis.

Rare reported risks: anaphylaxis, migration of filler, permanent hard nodules, blindness, stroke and death.

Two findings from Allergan's own studies show the span the company reported: in the Voluma XC cheek study the most common side effects were moderate and generally lasted 2 to 4 weeks; in the Volbella XC lip study they were mild or moderate and generally resolved within 30 days.

Delayed-onset nodules are documented with Allergan's Vycross-technology fillers (Volbella, Vollure, Voluma): a Canadian clinic series of 2,139 patients counted them in 0.33% of patients, and an earlier US chart review put Volbella XC at 1.0% per patient, with none seen for Vollure or Voluma; every nodule in the US series resolved with steroid injection plus hyaluronidase.

These are single-clinic figures, not product-wide rates.

Labeling also sets exclusions.

Juvederm's ISI says the products should not be used by anyone with a history of multiple severe allergies or anaphylaxis, an allergy to lidocaine or to the gram-positive bacterial proteins used in the products, or prior allergic reactions to hyaluronic acid fillers.

FDA adds that filler safety is unknown during pregnancy and breastfeeding, and that treatment should be delayed if the skin in the area is inflamed or infected.

Aftercare, per Juvederm's labeling: avoid makeup for 12 hours after treatment, and minimize strenuous exercise, extensive sun or heat exposure and alcohol for the first 24 hours, because these may cause temporary redness, swelling and/or itching.

Reversal is not an undo button.

Allergan's ISI states that the effectiveness of removal of any dermal filler has not been studied, and FDA-approved hyaluronidase products such as Hylenex are approved only to aid subcutaneous fluid administration, increase the dispersion and absorption of other injected drugs, and in subcutaneous urography — so using hyaluronidase to dissolve filler is off-label.

The brand-to-brand comparison for Juvederm is Restylane, Galderma's hyaluronic acid filler family.

Both lines work the same legal way — each product carries its own FDA-approved indications — so the comparison that matters is product by product, not brand versus brand.

Three concrete differences from the approval record:

• Lips came first for Restylane: Restylane was approved for lip augmentation in 2011 (Restylane-L followed in 2012), the first US filler with a lip indication, while Juvederm's first lip approval was Ultra XC in 2015, followed by Volbella XC in 2016.
• Under the eyes came first for Juvederm: Volbella XC was approved for infraorbital hollowing in 2021, the first US filler approved there; Restylane Eyelight followed in 2023.
• The hands: only two US fillers are approved for hand rejuvenation — Radiesse (2015) and Restylane Lyft (2018). No Juvederm product is among them.

Longevity is where comparisons go wrong, because the two makers publish different kinds of figures.

Allergan says Volbella XC and Ultra XC can hold results in the lips for up to 1 year with optimal treatment — a manufacturer claim.

Restylane Kysse's own pivotal trial measured that 60% of 169 treated subjects were still lip-fullness responders at week 48 — a trial result.

Different products, different measures; neither figure predicts the other product's outcome, and neither predicts yours.

The rewards programs differ too.

Allergan's Allē gives 100 points = $10 toward qualifying treatments including Juvederm.

Galderma's ASPIRE program — for Restylane, Sculptra and other Galderma products — offers a $20-off welcome reward, 100 points = $10 in savings and up to 600 points per visit, per Galderma's Restylane site.

Program terms change, so check both before you book.

FDA advises choosing a licensed health care provider with dermatology or plastic-surgery experience who is trained in filler injection, and says filler injection should be considered a medical procedure, not a cosmetic treatment.

Product authenticity is part of the check.

FDA warns that unapproved versions of Juvederm — Juvederm Ultra 2, 3 and 4 — have been sold in the US, including online, and should not be used.

The agency also says no filler is approved for over-the-counter use and advises people not to inject themselves or buy filler online.

Training can even be product-specific: Allergan's ISI for Volbella XC says the under-eye treatment should be injected only by doctors who have completed Allergan's training.

For credentials, red flags and payment options across the whole med spa menu, the Med spa guide walks through the vetting checklist.